María Presa

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Randomized Controlled Trial

Antiretroviral Therapy

Health Insurance

Diffuse Large B Cell Lymphoma

Top Venues

PharmacoEconomics - open

Clinical rheumatology

ClinicoEconomics and outcomes research : CEOR

This page only lists publications with an associated author ORCID identifier.

Publications

Alejandro Martin Martin Garcia-Sancho, María Presa, Carlos Pardo, Victoria Martín-Escudero, Itziar Oyagüez, Valentín Ortiz-Maldonado
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain. Cancers 16 (13) (2024)
Raul Cordoba, Lucía López-Corral, María Presa, Victoria Martín-Escudero, Sachin Vadgama, Miguel Ángel Casado, Carlos Pardo
The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain. Cancers 16 (15) (2024)
Alejandro Martin Martin Garcia-Sancho, María Presa, Carlos Pardo, Victoria Martín-Escudero, Itziar Oyagüez, Valentín Ortiz-Maldonado
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain. Cancers 16 (13) (2024)
Raul Cordoba, Lucía López-Corral, María Presa, Victoria Martín-Escudero, Sachin Vadgama, Miguel Ángel Casado, Carlos Pardo
The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain. Cancers 16 (15) (2024)
María Presa, David Vicente, Antonio Calles, Laura Salinas-Ortega, Jaesh Naik, Luis F García, Javier Soto
Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain. ClinicoEconomics and outcomes research : CEOR 15 (2023)
Vicente Estrada, Miguel Górgolas, José A Peña, Elena Tortajada, Antonio Castro, María Presa, Itziar Oyagüez
Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain. PharmacoEconomics - open 6 (3) (2022)
Mariana Bastos-Oreiro, Ana de Las Heras, María Presa, Miguel A Casado, Carlos Pardo, Victoria Martín-Escudero, Anna Sureda
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain. Cancers 14 (3) (2022)
María Presa, Fernando Pérez-Ruiz, Itziar Oyagüez
Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. Clinical rheumatology 38 (12) (2019)